India is expected to be the third largest market for pharmaceuticals by the year 2020 in terms of incremental growth. India's filing of Drug Master Files's (DMF's) with USFDA as of December 2013 totals to 3411. This is the DMF highest filed by any country in the world. Total export of Drugs, Pharmaceuticals by India for the year 2013-14 at USD 15,095 million, saw a record growth rate of 2.5 per cent over the corresponding period of previous years.
Select stocks from the pharma industry are showing a whopping growth. Here are 6 stocks that have given the best returns in the last one year.
Robust growth going forward
The healthcare sector of the Country is expected to grow to USD 250 Billion by the year 2020 from USD 65 Billion currently.
The generics market is expected to grow to USD 26.1 Billion by 2016 from USD 11.3 Billion in 2011.
This is solid growth by any stretch of imagination. In fact, revenues for the industry have more than doubled in the last 5 years.
Nifty pharma index
The Nifty Pharma Index fell from a high of 13489 in October 2015 to 10335 approximately in the end of June, post Brexit.
However in the last two months the index showed some signs of recovery.
Piramal Enterprises has given the best return in the last 1 year by giving a huge movement of 115.83 per cent.
Owing to the strong fundamental Piramal Enterprises is recommended as a multibagger stock by Dynamic Levels research team
Piramal Enterprises last closed the day at Rs 1,902 on the NSE.
The next best performer of the lot is Divis Lab. Since Budget the share gave a movement of 41.76 per cent.
Divis lab is one of the Top 500 shares suggested by Dynamic Levels. Divis Lab share price last closed at Rs 1,338 on the NSE.
Divis has a plant in Hyderabad with 500 acre site and the plant comprises of 13 multi-purpose production.
Shasun is another pharma company that has performed well in the last one year. The stock has gained almost 28 per cent in the last 1 year.
The company offers formulation and generic manufacturing services at its India sites together with a contract research and manufacturing service for APIs (Active Pharmaceutical Ingredients) in India and the UK.
Disclaimer: The contents of the article is sourced from the research report of Dynamic Levels with due permission. Dynamic Levels is a website owned by Dynamic Equities Pvt Limited, a member of BSE and NSE. You can visit Dynamic Levels by clicking: Dynamic Levels The article is not a solicitation to buy, sell in securities or other financial instruments. Greynium Information Technologies Pvt Ltd, its subsidiaries, associates and Dynamic Levels do not accept culpability for losses and/or damages arising based on information in this article.